Emil B.
- Country
- Bulgaria
- Department
- Dermatology and Venereology
Research Overview
- Phase 1 Evaluation of VIS171 Safety, Tolerability, Pharmacodynamics, Pharmacokinetics, and Immunogenicity in Autoimmune Conditions: Alopecia Areata, Systemic Lupus Erythematosus, and Immune-Mediated Focal Segmental Glomerulosclerosis
- A multicenter, randomized, participant- and investigator -blinded, placebo-controlled, phase 2a study to assess the efficacy, safety and tolerability of GIA632 in adult participants with moderate to severe atopic dermatitis
- A multicenter, double-blind, randomized, placebo-controlled, parallel-group, twelve-week treatment proof-of-concept trial to explore the efficacy and safety of IDOR-1117-2520 in adults with moderate to severe chronic plaque psoriasis with or without psoriatic arthritis.
Data & Insights
Has run more than one trial at 3 of 32 partner sites.
Specializations
Dermatology and Autoimmune Skin Disease
Emil Bardarov is involved in clinical research focused on inflammatory and immune-mediated skin disorders, with activity in psoriasis, atopic dermatitis, and alopecia areata. His trial portfolio also includes cutaneous lupus presentations such as discoid lupus erythematosus and subacute cutaneous lupus erythematosus.
- Moderate to severe plaque psoriasis
- Atopic dermatitis
- Alopecia areata
- Cutaneous lupus erythematosus
His research landscape reflects a strong therapeutic interest in immune-modulating approaches for chronic dermatologic disease and related inflammatory conditions.
Gastroenterology and Hepatic Disease
His clinical research includes treatment areas in ulcerative colitis, inflammatory bowel disease, and hepatic encephalopathy, alongside studies in chronic viral liver disease such as chronic hepatitis B and chronic hepatitis D.
- Ulcerative colitis
- Inflammatory bowel disease
- Hepatic encephalopathy
- Chronic hepatitis B infection
This area of interest spans both inflammatory gastrointestinal disorders and liver-related complications requiring targeted therapeutic intervention.
Cardiovascular and Thrombotic Risk
Emil Bardarov is active in studies addressing heart failure, atrial fibrillation, acute myocardial infarction, hypertension, and broader atherosclerotic cardiovascular disease. His work also extends to prevention of venous thromboembolism and other thrombotic complications.
- Heart failure with preserved or mildly reduced ejection fraction
- Atrial fibrillation
- Acute myocardial infarction
- Venous thromboembolism
His therapeutic focus includes cardiovascular event reduction, lipid-related risk, and clot-prevention strategies in high-risk patient groups.
Metabolic and Lipid Disorders
His trial involvement also covers hypercholesterolemia, hypertriglyceridemia, severe hypertriglyceridemia, and obesity-associated cardiometabolic disease. These studies align with efforts to improve control of atherogenic lipids and reduce downstream cardiovascular risk.
- Hypercholesterolemia
- Hypertriglyceridemia
- Severe hypertriglyceridemia
- Obesity-related cardiovascular risk
He is also engaged in research relevant to metabolic inflammation and conditions linked to elevated cardiovascular burden.
Respiratory, Ophthalmic, and Other Immune-Mediated Conditions
Additional research interests include chronic obstructive pulmonary disease, non-cystic fibrosis bronchiectasis, open-angle glaucoma, ocular hypertension, relapsing multiple sclerosis, rheumatoid arthritis, and Sjögren's syndrome.
- Chronic obstructive pulmonary disease
- Non-cystic fibrosis bronchiectasis
- Open-angle glaucoma
- Relapsing multiple sclerosis
His clinical portfolio includes therapeutic areas spanning airway disease, eye disease, and systemic immune-mediated disorders.
Related Investigators
Researchers in similar fields or departments
Want to know more about this investigator?
We can share extended profile information and contact details.
Is something out of date?
Tell us what needs correcting and we'll update this profile.